CollPlant Biotechnologies Ltd.
CLGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $11 | $0 | $16 |
| % Growth | -95.3% | 3,565.2% | -98.1% | – |
| Cost of Goods Sold | $3 | $3 | $1 | $2 |
| Gross Profit | -$2 | $8 | -$1 | $14 |
| % Margin | -417.1% | 71.8% | -393.6% | 87.2% |
| R&D Expenses | $11 | $10 | $10 | $8 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5 | $5 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15 | $15 | $16 | $14 |
| Operating Income | -$17 | -$8 | -$17 | $0 |
| % Margin | -3,349.7% | -68.5% | -5,718.1% | 0.4% |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$17 | -$7 | -$17 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$7 | -$17 | $0 |
| % Margin | -3,225% | -64% | -5,660.5% | 1.5% |
| EPS | -1.45 | -0.62 | -1.52 | 0.041 |
| % Growth | -133.9% | 59.2% | -3,807.3% | – |
| EPS Diluted | -1.45 | -0.62 | -1.52 | 0.034 |
| Weighted Avg Shares Out | 11 | 11 | 11 | 10 |
| Weighted Avg Shares Out Dil | 11 | 11 | 11 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$16 | -$6 | -$16 | $1 |
| % Margin | -3,020.2% | -53.9% | -5,289.3% | 6.7% |